SCHEMBL1157604

SCHEMBL1157604

O=C(O)C(CS)NCCO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
THRB P10828 1/20 0.48
ALOX15 P16050 1/20 0.48
NFKB1 P19838 1/20 0.48
PTGS2 P35354 1/20 0.48
THPO P40225 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ACE P12821 1/20 0.44
FOLH1 Q04609 2/20 0.41
GGT1 P19440 1/20 0.36
PTGS1 P23219 1/20 0.36
SLC7A11 Q9UPY5 1/20 0.36
TGFBR1 P36897 3/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313273 1.00 MAPT (0.48) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL3137754 1.00 MAPT (0.48) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL900182 0.88 KDM4E (0.54) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL900178 0.88 KDM4E (0.54) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL17378062 0.88 KDM4E (0.54) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL27481030 0.87 KDM4E (0.45) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL27481029 0.87 KDM4E (0.45) MAPTKDM4ETHRBALOX15NFKB1
Hydrochloric Acid SCHEMBL16993797 0.86 KDM4E (0.52) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL7259702 0.84 KDM4E (0.50) MAPTKDM4ETHRBALOX15NFKB1
Ethylene SCHEMBL28132201 0.84 KDM4E (0.50) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2688578-B1 MIA (MELANOMA INHIBITORY ACTIVITY) INHIBITORS FOR PREVENTING AND CURING VITILIGO BORDIGNON MATTEO (IT) 2019-03-27 EP claimed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
CN-113316568-A 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin 全球血液疗法股份有限公司 2021-08-27 CN disclosed
CN-106316982-B Thiazine amide derivative and use thereof 中国人民解放军军事医学科学院毒物药物研究所 2020-08-14 CN disclosed
US-10335417-B2 Thiazideamide derivative and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2019-07-02 US disclosed
US-20190192691-A1 REGULATED BIOCIRCUIT SYSTEMS OBSIDIAN THERAPEUTICS, INC. 2019-06-27 US disclosed
US-20180185376-A1 Thiazideamide Derivative and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2018-07-05 US disclosed
EP-3335720-A1 C-DI-GMP BINDING PEPTIDES Universität Basel (CH) 2018-06-20 EP disclosed
EP-3327010-A1 THIAZIDEAMIDE DERIVATIVE AND USE THEREOF Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) 2018-05-30 EP disclosed
EP-2889293-B1 THIAZINE AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF INST PHARMACOLOGY & TOXICOLOGY ACAD MILITARY MEDICAL SCIENCES PLA CHINA (CN) 2017-04-26 EP disclosed
US-7361711-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-22 US disclosed
US-7358309-B2 core or the layer includes a composition formed from a base polymer, a crosslink initiator, and at least one additive; additive has at least one carbon-oxygen-boron linkage, carbon in the linkage being a secondary or tertiary carbon; enhances coefficient of restitution and/or reduces compression of core ACUSHNET COMPANY (US) 2008-04-15 US disclosed
US-7358310-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-15 US disclosed
US-7358308-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-15 US disclosed
US-20060281586-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2006-12-14 US disclosed
US-20060281587-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2006-12-14 US disclosed
US-20050245657-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2005-11-03 US disclosed
US-20050245652-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2005-11-03 US disclosed
US-4487780-A SUBSTITUTED CYSTEINE COMPOUNDS SCHEINBERG ISRAEL H 1984-12-11 US disclosed
US-4315028-A COPPER OR GOLD COMPLEX OF PENICILLAMINE SCHEINBERG ISRAEL H 1982-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10335417-B2 Thiazideamide derivative and use thereof TREH, AQP4, TST MAPT 31/4885KDM4E 2027/4885THRB 1120/4885
US-20180185376-A1 Thiazideamide Derivative and Use Thereof TREH, AQP4, TST MAPT 31/4885KDM4E 2027/4885THRB 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.